In memoriam: Dr. Karel De Beule

In Memoriam: Karel De Beule
In Memoriam: Karel De Beule

Post provided by Dr. Beule’s colleagues at Tibotec.

In memoriam: Karel De Beule, PharmD, MBA (July 8, 1958 – April 6, 2010) following an outstanding 24+ year career in the pharmaceutical industry; Karel will be remembered for his contributions to pharmaceutical development in the infectious disease area, starting with the Janssen Pharmaceutica antifungal portfolio, which included itraconazole in the 1980-90’s, followed by his involvement from 2004 to 2010 with the novel TB drug, TMC 207, as compound development team leader at Tibotec. He was instrumental in establishing the landmark collaboration between Tibotec and the TB Alliance to accelerate TB drug development.

His unwavering dedication to the TB field will be remembered and sorely missed.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...